Breakthrough and Accessibility: Boao Lecheng’s Third Batch of Stem Cell Therapies Sets New Standards in Regenerative Medicine

The landscape of regenerative medicine in China continues to evolve at a remarkable pace, with the Boao Lecheng International Medical Tourism Pilot Zone solidifying its position as the nation’s premier gateway for cutting-edge cellular and gene therapies. The recent announcement of their third batch of approved technologies marks another significant milestone in making these advanced treatments available to patients.

Disclosure of the Third Batch: Timing and Venue

On August 30, 2025, the Hainan Boao Lecheng International Medical Tourism Pilot Zone hosted a Policy Promotion Conference on Biomedical New Technologies. It was at this event that the pricing and implementing hospital information for the third batch of cell and gene therapy medical (new technologies) were first publicly disclosed. This event underscored Lecheng’s role as a clinical transformation “testing ground” and a hub for introducing international advanced medical technologies under its special policies.

Examining the Three New Approved Technologies

This latest batch comprises three innovative therapies, each targeting distinct clinical challenges and featuring a gradient pricing structure aimed at enhancing patient accessibility.

1. Anti-EBV Infected Cell Vaccine Therapy

Target Patients: Individuals with diseases associated with Epstein-Barr virus (EBV) infection, such as nasopharyngeal carcinoma and lymphoma. This technology offers a novel preventive and therapeutic strategy.

Treatment Method: A cell vaccine approach designed to combat EBV infection. The specifics of the cell type (likely immune cells) were not detailed in the sources, but it aims to elicit an immune response against EBV-associated pathologies.

Cost: CNY 16,000 per single treatment session.

Implementing Hospital: West China Hospital.

2. Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Pulmonary Fibrosis

Target Patients: Patients suffering from pulmonary fibrosis, a condition with limited treatment options and often a poor prognosis.

Treatment Method: Utilizes mesenchymal stem cells derived from menstrual blood. These cells are believed to leverage their multi-directional differentiation potential and immunomodulatory functions to repair damaged lung tissue and regulate the local immune microenvironment in the lungs.

Cost: CNY 140,000 per treatment course.

Implementing Hospital: Shulan Hospital.

3. Umbilical Cord Mesenchymal Stem Cell Therapy for Premature Ovarian Insufficiency

Target Patients: Women affected by premature ovarian insufficiency (POI), a condition leading to declined ovarian function before the age of 40, often resulting in infertility and hormonal deficiencies.

Treatment Method: Involves the use of umbilical cord-derived mesenchymal stem cells. The proposed mechanism of action is through improving the local ovarian microenvironment and promoting follicular development, thereby potentially restoring ovarian function.

Cost: CNY 80,000 per single treatment session.

Implementing Hospital: Ciming Hospital.

A Look Back: The First and Second Batches

The third batch builds upon the foundation laid by the first two rounds of approvals, which already addressed a wide spectrum of diseases.

The First Batch (Announced in March 2025)

Unveiled during the Second Boao Lecheng Stem Cell Conference on March 22, 2025, the first batch consisted of three technologies with an approval rate of just approximately 3%. It focused on high-incidence, difficult-to-treat diseases:

Umbilical Cord Mesenchymal Stem Cell Injection for Knee Osteoarthritis: Priced at CNY 36,000 per injection (intra-articular injection), administered at Ruijin Hospital Hainan Hospital.
Airway Basal Layer Stem Cell Therapy for Chronic Obstructive Pulmonary Disease (COPD): Priced at CNY 150,000 per session (autologous cell transplant), administered at Ruijin Hospital Hainan Hospital.
Human Umbilical Cord-Derived MSCs for Improving Heart Failure with Reduced Ejection Fraction (HFrEF): Priced at CNY 60,000 per session (3 sessions constituting a course), administered at West China Hospital Lecheng Hospital.

The Second Batch (Announced in April 2025)

Released during the 2025 Boao Stem Cell Industry Congress (closed-door session on April 26, 2025), this batch expanded the scope into oncology and genetic eye diseases, and notably included the first gene therapy. It comprised five technologies:

Personalized DC Vaccine for Malignant Tumors: CNY 150,000 per session (6-7 sessions/course) – West China Hospital Lecheng Hospital.
Mesenchymal Stem Cell Therapy for Graft-versus-Host Disease (GVHD) post-bone marrow transplant: CNY 80,000 per session – West China Hospital Lecheng Hospital.
Airway Basal Layer Stem Cell Therapy for Interstitial Lung Disease: CNY 150,000 per course – Ruijin Hospital Hainan Hospital.
Airway Basal Layer Stem Cell Therapy for Bronchiectasis: CNY 150,000 per course – Ruijin Hospital Hainan Hospital.
Gene Therapy for RPE65 Biallelic Mutation-related Inherited Retinal Dystrophy: CNY 480,000 per single eye – Ruijin Hospital Hainan Hospital.

The pricing for the GVHD treatment, for instance, was noted to be about one-sixth of the cost in the United States (approximately USD 500,000 per session there), highlighting Lecheng’s commitment to accessibility.

Rigorous Scrutiny: The Foundation of Trust

A critical aspect of Lecheng’s model is its stringent review process, which ensures that only technologies with substantial scientific backing are approved for clinical application. All (declared) projects undergo a joint review by a multidisciplinary expert group spanning seven disciplines, including (academicians), ethics, preparation (manufacturing), and clinical experts.

The approval criteria are demanding. Projects must meet at least one of the following conditions:

Have entered the Phase II clinical trial stage
Be an IIT (Investigator-Initiated Trial) project filed with the relevant national departments
Have support from large hospital expert teams and data

This meticulous mechanism ensures the safety, efficacy, and quality controllability of the approved projects. The low approval rate—only around 3% for the first batch (3 out of over 200 applications) and a total of 11 approved projects out of 31 reviewed across three assessment meetings—speaks volumes about the selectivity and rigor employed.

Conclusion: A Calculated Leap Forward

The disclosure of the third batch of cell and gene therapies at Boao Lecheng is more than just a list of new medical services; it represents a carefully orchestrated effort to integrate advanced regenerative medicines into clinical practice within a framework of scientific rigor, ethical consideration, and growing patient accessibility.

The gradient pricing strategy observed across the batches, from CNY 16,000 for the anti-EBV vaccine to CNY 480,000 for the genetic eye therapy, is a pragmatic approach to cater to patients with varying financial capabilities while providing reference for future potential inclusion in insurance schemes. Industry experts optimistically project that within the next three to five years, with optimized production processes and increased capacity, the cost of stem cell therapies could drop to the ten-thousand-yuan level, potentially achieving (medical insurance coverage) and truly allowing cutting-edge medical technologies to benefit the general public.

Boao Lecheng’s “pilot” policy, allowing the use of technologies not yet fully approved nationwide but subjected to its own strict evaluation, has created a unique and vital space for China to gather real-world clinical data and experience. It accelerates the transformation from laboratory research to clinical application, bridges a critical gap for patients with urgent needs, and continuously propels the standardized and internationalized development of China’s cell and gene therapy industry. As these technologies demonstrate their value and stability through more extensive application and longer-term follow-up in Lecheng, they pave the way for broader adoption across the country, ultimately offering new hope to countless patients.